ASGCT News

ASGCT Member Access Will Be Unavailable for Scheduled Service Oct. 5-11

ASGCT Staff | October 04, 2022

ASGCT member services, including logins, applications to join, event registrations, and Molecular Therapy access, will be unavailable from EOB October 5-11 as part of a planned database migration.

Read Full Story

Insight Series is Back with CAR T-Cell Therapy & GT Delivery to Skeletal Muscles

Grant Holley, PhD | September 30, 2022

The Insight Series is back with two sessions in October on CAR T-cell therapy and gene therapy delivery to skeletal muscles.

Read Full Story

ASGCT Members Speak at House CAR T-Cell Therapy Briefing

ASGCT Staff | September 29, 2022

Watch today's briefing on CAR T-cell therapy and patient access.

Read Full Story

Watch the 2022 Policy Summit On Demand Through Oct. 27

ASGCT Staff | September 27, 2022

Didn't register? You can still do so to access on-demand sessions!

Read Full Story

Gene Therapies for SCD, Beta Thalassemia Need Further Development Despite Promising Results

Stefano Rivella, PhD | September 22, 2022

During Sickle Cell Awareness Month, Dr. Rivella explains the status of gene therapies for hemoglobinopathies.

Read Full Story

FDA Approves SKYSONA, Second Lentiviral Vector Gene Therapy in the U.S.

Hans-Peter Kiem, MD, PhD | September 20, 2022

The approval of SKYSONA® comes one month after the first lentiviral vector gene therapy, Zynteglo, was approved for use in the U.S.

Read Full Story

ASGCT’s Inaugural Lab Week Brings MPS Teachers Back to School

Grant Holley, PhD | September 09, 2022

This past summer, we worked with Milwaukee teachers on science experiments that we hope they'll take back to their classrooms.

Read Full Story

What Can You Do to Increase Access to Gene & Cell Therapy?

Kenneth Cornetta, MD | September 09, 2022

Dr. Cornetta talks about the latest efforts of the Global Outreach Committee and encourages people in the field to spread the word.

Read Full Story

ASGCT Calls for Changes to Synthetic DNA Screening Guidance

Paloma Giangrande, PhD | September 06, 2022

Dr. Giangrande explains ASGCT’s recent comments on a proposed update to the Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA.

Read Full Story

Patient Education Program Continues to Expand Gene Therapy Resources

Kenji Rowel Lim, PhD | August 30, 2022

As it approaches its five-year anniversary in January, ASGCT's Patient Education Program continues to evolve.

Read Full Story

Beti-Cel Becomes the First Lentiviral Vector Gene Therapy in the U.S.

Hans-Peter Kiem, MD, PhD | August 17, 2022

The approval of beti-cel represents a huge step forward for beta thalassemia patients, giving them the option to pursue a one-and-done treatment approach.

Read Full Story

ASGCT-ISSCR Symposium Highlights Regenerative Medicine Advancements

David Barrett, JD | August 15, 2022

ASGCT CEO David Barrett, JD, talks about the benefits of attending the ASGCT-ISSCR Symposium Sept. 21-23.

Read Full Story

Better Understanding of AAV Integration is Necessary to Inform Patient Care

Denise Sabatino, PhD | July 22, 2022

Dr. Denise Sabatino explains key takeaways of an article she coauthored on AAV integration that is now available in Molecular Therapy.

Read Full Story

Molecular Therapy Reaches Highest-Ever Impact Factor of 12.9

Roland Herzog, PhD | July 19, 2022

Molecular Therapy's impact factor reached 12.9 in 2021, the highest in its history.

Read Full Story

Register for the 2022 Policy Summit

ASGCT Staff | July 11, 2022

Join us Sept. 26-27 in person in Washington, D.C. or virtually for the fourth annual Policy Summit.

Read Full Story

User Fee Negotiations Heat Up Ahead of September 30 Reauthorization Deadline

Margarita Valdez Martínez & Caitlin McCombs, MBA | June 30, 2022

Learn more about the different versions of a bill moving through Congress that includes the reauthorization of the Prescription Drug User Fee Authorization (PDUFA) Act.

Read Full Story